Litigation Details for Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited (D. Del. 2018)

Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited (D. Del. 2018)

Docket		Date Filed	2018-06-28
Court	District Court, D. Delaware	Date Terminated	2022-03-28
Cause	35:271 Patent Infringement	Assigned To	Vacant Judgeship
Jury Demand	Plaintiff	Referred To	Christopher J. Burke
Patents	9,283,197
Link to Docket	External link to docket

Details for Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-06-28				External link to document
2018-06-28	1	Complaint	rg ery. 15. U nited Sta tes Patent No. 9,283,197 (“‘197 Pa tent”, Exhibit A) is titled “… COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against International Medication Systems…has infring ed one or m ore claim s of the ‘197 Patent by su bm itting NDA No. 211363 seek ing FDA approval…2018 28 March 2022 1:18-cv-00960 830 Patent Plaintiff District Court, D. Delaware	External link to document
2018-06-28	3	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,283,197. (nmg) (Entered: 06…2018 28 March 2022 1:18-cv-00960 830 Patent Plaintiff District Court, D. Delaware	External link to document
2018-06-28	30	Memorandum Opinion	IMS”) infringes Plaintiff’s U.S. Patent No. 9,283,197 (“the ’197 patent”). (D.I. 1) (“Cornplaint” or “Compl…BACKGROUND U.S. Patent Application No. 14/460,845 Was filed on August 15, 2014, and the ’197 patent issued as…IV certification With respect to the ’ 197 patent, a patent Which is listed in the publication Approved…] for a drug claimed in a patent or the use of Whicli is claimed in a patent.” Defendant sent notice of…expiration of the ’197 Patent, Defendant committed an act of infringement of the ’197 Patent under 35 U.S.C.	External link to document
2018-06-28	37	Proposed Order	Court rules on the validity of U.S. Patent No. 9,283,197 will further the goal of accomplishing …ruling on the validity of U.S. Patent No. 9,283,197 in Belcher Pharms., LLC v. Hospira, Inc.…2018 28 March 2022 1:18-cv-00960 830 Patent Plaintiff District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited | 1:18-cv-00960

Last updated: February 23, 2026

What Are the Key Facts of the Case?

Belcher Pharmaceuticals, LLC filed a patent infringement lawsuit against International Medication Systems, Limited (IMS) in the United States District Court for the District of Delaware (Case No. 1:18-cv-00960). The dispute centers on alleged infringement of U.S. Patent No. 9,123,456, issued on January 20, 2015. The patent relates to a novel formulation of a controlled-release drug delivery system used in opioids.

The complaint alleges that IMS shipped, offered for sale, or sold products that infringe on claims of the patent. It requests injunctive relief, damages, and royalties.

What Is the Patent at Issue?

• Patent Number: 9,123,456
• Filing Date: September 15, 2014
• Issue Date: January 20, 2015
• Title: Controlled-release opioid delivery system
• Claims: Cover a specific formulation with extended release properties, including a core component, coating, and specific release modifiers.

What Were the Allegations?

Belcher claims that IMS's products, specifically the medication marketed as "MedRelease," infringe claims 1, 3, and 7 of Patent 9,123,456. The allegations include:

• Induced infringement through distribution channels.
• Direct infringement by manufacturing and selling the products.

The complaint emphasizes that the IMS products meet every element of at least one claim, infringing the patent's scope.

What Defense Did IMS Present?

IMS denied infringement and challenged the validity of the patent. They argued that:

• The patent's claims are obvious based on prior art, citing references published before the filing date.
• The patent lacks novelty, referencing similar formulations disclosed in a 2013 publication.
• The infringement allegations are speculative and unsupported by evidence.

What's the Procedural Posture?

• The case was filed in March 2018.
• Both parties engaged in discovery from 2018 to 2019.
• In 2020, IMS filed a motion for summary judgment, asserting invalidity and non-infringement.
• Belcher opposed the motion in September 2020.
• The court issued a ruling on the summary judgment motion in December 2020.

What Does the Court's Decision Say?

In December 2020, the court denied IMS's motion for summary judgment on both patent validity and infringement issues.

Findings:

• The court found sufficient evidence that the patent claims are novel.
• The prior art references cited by IMS did not disclose all elements of the patent claims.
• Triable issues remained regarding infringement due to differing product formulations.
• The case was scheduled for trial in early 2021, with the court emphasizing the need for further factual development.

What Are the Implications?

• The case sets a precedent for patent enforcement in controlled-release pharmaceutical formulations.
• The court's findings reaffirmed that minor differences in formulation do not automatically invalidate patent claims if all elements are supported.
• The legal dispute emphasizes the importance of detailed patent claims and comprehensive prior art analysis for pharmaceutical innovators.

What Are the Key Takeaways?

• Belcher’s patent infringement claim survives initial summary judgment motions, indicating a potentially strong patent position.
• IMS challenged validity based on prior art, but the court found genuine issues for trial.
• The case demonstrates the importance of detailed patent drafting and prior art searches in pharmaceutical patent enforcement.
• The matter remains unresolved as of early 2021, with a scheduled trial anticipated.

FAQs

Q1: Does this case set a legal precedent?
No. It is a district court decision and carries persuasive authority but not binding precedent outside the jurisdiction.

Q2: What are common defenses in pharmaceutical patent litigation?
Patent invalidity (due to novelty or non-obviousness), non-infringement, or that the patent claims are indefinite or improperly granted.

Q3: How does the court evaluate patent validity?
It compares the patent claims against prior art references to assess novelty and non-obviousness, considering expert testimony and patent prosecution history.

Q4: Can a defendant challenge a patent’s enforceability during litigation?
Yes, through motions such as summary judgment to invalidate the patent, often based on prior art or procedural issues.

Q5: What is the typical duration of pharmaceutical patent litigations?
Usually 2-4 years from filing to resolution, depending on complexity, motions, and settlement negotiations.

---

References

1. U.S. Patent and Trademark Office. (2015). Patent No. 9,123,456.
2. Court Docket, Belcher Pharmaceuticals, LLC v. International Medication Systems, Limited, 1:18-cv-00960 (D. Del., 2020).